Serum YKL-40, a prognostic marker in patients with large-artery atherosclerotic stroke.
Acta Neurol Scand
; 136(2): 97-102, 2017 Aug.
Article
em En
| MEDLINE
| ID: mdl-27650381
ABSTRACT
BACKGROUND AND PURPOSE:
Inflammation comprises important aspects of large-artery atherosclerosis (LAA) stroke pathophysiology. YKL-40 is a new and emerging biomarker that is associated with both acute and chronic inflammations. Elevated serum concentrations of YKL-40 have been reported in patients with atherosclerosis and other cardiovascular diseases. This study investigates whether serum YKL-40 concentrations on admission can predict 3-month clinical outcomes after LAA stroke.METHODS:
We recruited control patients (n=85) and those with LAA stroke (n=141) according to the TOAST classification system. The modified Rankin scale at 3 months after stroke was used to evaluate the prognosis. The prognostic accuracy was assessed by the receiver operating characteristic curve.RESULTS:
Serum YKL-40 level was significantly higher for LAA patients than for controls (P<.001). Patients with poor outcomes (n=36) had significantly increased serum YKL-40 concentrations on admission (P=.01). High YKL-40 levels predicted poor functional outcome (OR=6.47, P=.02). Moreover, the combination of YKL-40 level and the NIHSS score could improve the prognostic accuracy of the NIHSS in predicting functional outcome (combined areas under the curve, 0.87; 95% CI, 0.80-0.94; P<.001).CONCLUSIONS:
The level of serum YKL-40 is a significant and independent biomarker to predict the clinical outcome of LAA stroke.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Artérias Cerebrais
/
Acidente Vascular Cerebral
/
Aterosclerose
/
Proteína 1 Semelhante à Quitinase-3
Tipo de estudo:
Prognostic_studies
Limite:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
País/Região como assunto:
Asia
Idioma:
En
Revista:
Acta Neurol Scand
Ano de publicação:
2017
Tipo de documento:
Article
País de afiliação:
China